Genzyme

Jump to: navigation, search
<tr class="logo"><td colspan="2" style="text-align:center; padding:16px 0 16px 0;">Genzyme logo.gif</td></tr> <tr class="note"><th style="text-align:right; padding-right:0.75em;">Type</th><td>Public</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Founded</th><td>Boston, Massachusetts, USA (1981)</td></tr><tr><th style="text-align:right; padding-right:0.75em;">Headquarters</th><td class="adr">Cambridge, Massachusetts, United States</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Key people</th><td>Henri A. Termeer, Chairman of the Board and C.E.O.</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Industry</th><td>biotechnology</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Products</th><td>Cerezyme®
Fabrazyme®
Synvisc®
Renagel®
More Complete Product List</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Revenue</th><td>US $3.19billion (2006 calendar)[1]</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Operating income</th><td>US $190.5 million (2006 calendar)[1]</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Net income</th><td>US $16.8 million (2006 calendar)[1]</td></tr><tr class="note"><th style="text-align:right; padding-right:0.75em;">Employees</th><td>apprx. 9,000 (Dec. 31, 2006)[1]</td></tr><tr><th style="text-align:right; padding-right:0.75em;">Website</th><td class="url">www.genzyme.com</td></tr>
Genzyme Corporation

WikiDoc Resources for

Genzyme

Articles

Most recent articles on Genzyme

Most cited articles on Genzyme

Review articles on Genzyme

Articles on Genzyme in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Genzyme

Images of Genzyme

Photos of Genzyme

Podcasts & MP3s on Genzyme

Videos on Genzyme

Evidence Based Medicine

Cochrane Collaboration on Genzyme

Bandolier on Genzyme

TRIP on Genzyme

Clinical Trials

Ongoing Trials on Genzyme at Clinical Trials.gov

Trial results on Genzyme

Clinical Trials on Genzyme at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Genzyme

NICE Guidance on Genzyme

NHS PRODIGY Guidance

FDA on Genzyme

CDC on Genzyme

Books

Books on Genzyme

News

Genzyme in the news

Be alerted to news on Genzyme

News trends on Genzyme

Commentary

Blogs on Genzyme

Definitions

Definitions of Genzyme

Patient Resources / Community

Patient resources on Genzyme

Discussion groups on Genzyme

Patient Handouts on Genzyme

Directions to Hospitals Treating Genzyme

Risk calculators and risk factors for Genzyme

Healthcare Provider Resources

Symptoms of Genzyme

Causes & Risk Factors for Genzyme

Diagnostic studies for Genzyme

Treatment of Genzyme

Continuing Medical Education (CME)

CME Programs on Genzyme

International

Genzyme en Espanol

Genzyme en Francais

Business

Genzyme in the Marketplace

Patents on Genzyme

Experimental / Informatics

List of terms related to Genzyme


Genzyme Corporation is a biotechnology company based in Cambridge, Massachusetts. Genzyme is the world’s third biggest biotechnology company employing over 9,000 people around the world. At present, the company has approximately 80 locations in 40 countries. It includes 17 manufacturing facilities and 9 genetic testing laboratories. The company’s products are available in nearly 90 countries. In 2006, Genzyme generated $3.2 billion in revenues with more than 25 products in the world’s markets. The company is also involved in philanthropic acts, donating $83 million in global product donations and $11 million in cash contributions in 2006. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for.” Additionally in 2007, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the President of the United States to America’s leading innovators.

Genzyme headquarters in Cambridge, MA

The company, started by a small group of scientists in 1981, was primarily devoted to finding drugs that would cure enzyme deficiency conditions that were essential to one’s survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are termed “orphan drugs.” In 1986, the company went public raising $27 million.

Genzyme focuses on six areas of medicine relating to lysosomal storage diseases, renal disease, orthopedics, transplant and immune diseases, oncology, genetics and diagnostics. The first orphan-drug for Genzyme that FDA approved was Ceredase, a drug for treating Gaucher disease. Other important drugs made by Genzyme are Renagel, used in treatment of dialysis patients, and Fabrazyme, used to treat patients with Fabry's disease. Other products in development are Tolevamer for Clostridium dificile colitis disease and Campath for multiple sclerosis.

Genzyme has a sub-license from Bioenvision to market Clofarabine in North America. Bioenvision has the rights to Clofarabine in the rest of the world. On Tuesday, May 29, 2007 Genzyme made a tender offer to purchase Bioenvision for $5.60 per share. Bioenvision management and the board of directors tendered their shares via an agreement prior to the announcement. However, not many other shareholders did and the tender offer closed without Genzyme acquiring their necessary 51% of Bioenvision. It remains to be seen if Genzyme will just be a shareholder of Bioenvision or proceed with a higher subsequent offer.

In 2006, CEO, President, and Board Chairman Henri Termeer, earned a salary of $1.4 million, and non-cash compensation worth $21 million.[2]

Product Listing

Cerezyme®
Fabrazyme®
Aldurazyme®
Myozyme®
Renagel®
Hectorol®
Synvisc®
Carticel®
Thymol Globulin®
Campath®
Clolar®
Thyrogen®
Sepra® family of products
Epicel®

References

External links


Linked-in.jpg